Background: Hyperfibrinolysis is one of the main causes of non-surgical bleeding during liver transplantation (LT). Viscoelastic haemostatic assays, including thromboelastometry (ROTEM ® ) and thrombelastography (TEG ® ), can detect
Editor's key points
• Hyperfibrinolysis is a leading cause of non-surgical bleeding during liver transplantation, and is detectable by point-of-care viscoelastic testing.
• In a prospective observational study, three assays were compared in 37 consecutive adult liver transplant patients.
• ROTEM ® was more sensitive than TEG ® in identifying hyperfibrinolysis, with FIBTEM ® being the most sensitive assay.
Liver transplantation (LT) is frequently associated with hyperfibrinolysis, which is one of the main causes of non-surgical bleeding during LT. 1 
Diagnosis of hyperfibrinolysis
Hyperfibrinolysis was detected per the manufacturers' definitions (maximum lysis >15% in ROTEM ® or Lysis30 >8% in TEG ® ), where maximum lysis is the reduction of clot firmness in relation to maximum clot firmness within the complete measurement period, and Lysis30 is the percentage reduction of amplitude compared with maximum amplitude (MA), which is measured at 30 min after the time of MA. None of the recently performed alternative hyperfibrinolysis thresholds was used in the current study. 4 The diagnosis of hyperfibrinolysis was confirmed with normalization of maximum lysis in simultaneously performed APTEM ® compared with maximum lysis measured in EXTEM ® . 
APTEM

Exclusion criteria for analysis
The entire set of VHA data performed simultaneously at each time point was excluded from analysis when any of the VHA measurements (1) were missed (not performed or not recorded as a result of technical reasons), or (2) showed a 'flat line' for more than 30 min. The latter is because of difficulty in differentiating hyperfibrinolysis from other causes (e.g., heparin administration) that lead to flat line.
Statistical analyses
Data are descriptively summarized as the number of measurement points or the number of LT patients with percentage. The sensitivities and specificities of three assays (k-TEG ® vs.
EXTEM ® vs. FIBTEM ® ) for identification of hyperfibrinolysis
were compared using McNemar's test. A P value <0.05 was considered statistically significant. Data were analysed using GraphPad Prism v4.0b (GraphPad Software, Inc. La Jolla, CA, USA).
Results
Patient characteristics
Thirty-seven subjects were enrolled and completed the study protocol. (Table 1) . Average age was 57 yr; 76% were male. The median Model for End-Stage Liver Disease (MELD) score was 18.
The most common aetiology of end-stage liver failure was postnecrotic cirrhosis (76%). Eight subjects (22%) received live donor grafts. ε-amino caproic acid was administered in 7 subjects who showed both bleeding in the surgical field and a hyperfibrinolysis pattern in k-TEG ® , especially based on the result of k-TEG ® at 30 min after graft reperfusion. Of 296 possible measurement points, 46 (16%) were excluded because of missing measurements of any one of the assays (27 measurement points) or flat line (19 measurement points) as detected in Table 2 .
Hyperfibrinolysis
Hyperfibrinolysis was confirmed in 89 (36%) of 250 measurement points ( [5] [6] [7] have replaced traditional laboratory-based diagnostic methods 8 9 including plasma values of D-dimer, thrombin/anti-thrombin complexes, tissue-type plasminogen activator antigen, and fibrin degradation products. In this study, hyperfibrinolysis was observed using VHA throughout the course of LT. Hyperfibrinolysis incidence was highest immediately after reperfusion, which another study also demonstrated. 5 Even at baseline, hyperfibrinolysis was detected and confirmed in 23% of patients, which is consistent with the reported incidence in liver cirrhosis patients. [10] [11] [12] 13 in an in vitro study using whole blood from healthy volunteers. FIBTEM ® is a modified EXTEM ® test in which the whole blood sample is activated with thromboplastin (recombinant tissue factor and phospholipids) with a heparin inhibitor and a platelet antagonist (cytochalasin D); the latter inhibits platelet cytoskeletal reorganization by disrupting actin microfilaments, and thus blocks fibrinogen/ 15 also demonstrated in a TEG ® experiment that abciximab, a glycoprotein IIb/IIIa receptor antagonist, abolished the platelet-induced masking effect of hyperfibrinolysis. They suggested that the contractility force transmitted via platelet glycoprotein IIb/IIIa receptors, which bind the polymerized fibrin network to the platelets' actin cytoskeleton, is the major contributor to clot strength. Therefore, a glycoprotein IIb/IIIa receptor antagonist (e.g., abciximab) prevents platelets from exerting contractile force on the fibrin network, which allows tPA, along with plasminogen, to bind to the fibrin surface and convert plasminogen to plasmin, leading to fibrinolysis. Since platelets are the source of continuous production of large amounts of active plasminogen activator inhibitor 1 (PAI-1), which stabilizes the blood clot, 16 inhibition of platelets might reduce the release of PAI-1. The lower sensitivity of k-TEG ® to EXTEM ® is noteworthy.
Thrombin activatable fibrinolysis inhibitor (TAFI) is activated by thrombin; activated TAFI (TAFIa) protects the fibrin clot by inhibition of tPA-mediated fibrinolysis. Conversion to TAFIa is greatly enhanced by high concentrations of thrombin. Nielsen and colleagues 17 demonstrated that TAFI primarily contributed to contact pathway protein-mediated attenuation of fibrinolysis, although they used plasma rather than whole blood. Unlike EXTEM ® , which uses tissue factor and phospholipids as activators, k-TEG ® uses kaolin, which is a contact pathway (or intrinsic pathway) activator. Use of the intrinsic pathway activator in k-TEG ® explains, at least in part, the lesser sensitivity of k-TEG ® in identifying hyperfibrinolysis. Of note, other than the activators or the additives in each assay, the mechanical feature of each VHA could also contribute to the difference found in the study, which could be checked performing the k-TEG ® assay in the ROTEM ® system and EXTEM ® assay in the TEG ® system. 
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